Umeclidinium - GlaxoSmithKline

Drug Profile

Umeclidinium - GlaxoSmithKline

Alternative Names: 573719; Ellipta Incruse; Encruse Ellipta; GSK-573719; Incruse; Incruse Ellipta; UMEC; Umeclidinium bromide

Latest Information Update: 21 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Benzhydryl compounds; Bronchodilators; Quinuclidines; Small molecules
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease
  • Phase II Asthma; Hyperhidrosis

Most Recent Events

  • 16 Feb 2018 Pharmacokinetics, adverse events and efficacy data from a phase IIa trial in Palmar hyperhidrosis presented at the 76th Annual Meeting of the American Academy of Dermatology (AAD-2018)
  • 08 Nov 2017 GlaxoSmithKline completes a phase III trial for Chronic obstructive pulmonary disease in South Korea and China(NCT02184611)
  • 03 Mar 2017 Adverse events data from a phase IIa trial in Hyperhidrosis presented at the 75th Annual Meeting of the American Academy of Dermatology (AAD-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top